Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amphastar Pharma
(NQ:
AMPH
)
48.56
+0.08 (+0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amphastar Pharma
< Previous
1
2
3
4
5
6
7
Next >
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
August 28, 2024
Via
ACCESSWIRE
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
August 07, 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
August 07, 2024
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024
July 31, 2024
Via
ACCESSWIRE
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
June 18, 2024
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each
Via
MarketBeat
Topics
ETFs
Economy
Exposures
Interest Rates
Why the growth investor may take a look at NASDAQ:AMPH.
June 05, 2024
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
Exploring NASDAQ:AMPH's growth characteristics.
May 15, 2024
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations
Via
Chartmill
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
June 04, 2024
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
June 03, 2024
Via
ACCESSWIRE
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
May 22, 2024
Via
ACCESSWIRE
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
May 16, 2024
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
May 09, 2024
Via
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
May 08, 2024
Via
ACCESSWIRE
NASDAQ:AMPH, an undervalued stock with good fundamentals.
March 12, 2024
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying.
Via
Chartmill
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
February 28, 2024
Via
ACCESSWIRE
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
May 08, 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
May 01, 2024
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
April 30, 2024
Via
ACCESSWIRE
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
April 10, 2024
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections...
Via
Benzinga
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
Via
ACCESSWIRE
Delving into NASDAQ:AMPH's Growth Prospects.
February 28, 2024
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing?
Via
Chartmill
Earnings Outlook For Amphastar Pharma
February 27, 2024
Via
Benzinga
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
February 14, 2024
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?
Via
Chartmill
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
March 06, 2024
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
February 20, 2024
Via
ACCESSWIRE
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
February 13, 2024
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
February 07, 2024
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.
Via
Chartmill
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
February 05, 2024
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.
Via
InvestorPlace
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.